Rani Therapeutics (RANI) announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical. The full analysis confirms the RaniPill delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied. “We are delighted to explore the opportunity of a collaboration with Chugai, a world-class industry leader with deep research and development capabilities and a reputation for bringing innovation to patients,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe Chugai’s technology-driven drug discovery approach for innovation and development capabilities aligns seamlessly with Rani’s expertise in developing oral antibodies, peptides, and large proteins with high bioavailability. At Rani, to date, we have evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill capsule, showcasing its broad applicability across a wide range of biologics.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics: Strategic Advancements in Obesity Treatment Justify Buy Rating
- Rani Therapeutics price target lowered to $4 from $14 at Oppenheimer
- Rani Therapeutics Highlights Promising Preclinical Data
- Rani Therapeutics: Strategic Progress and Promising Pipeline Justify Buy Rating
- Rani Therapeutics Faces Nasdaq Compliance Challenge